Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous
Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zhunyong Gu
- Phone Number: 8613918677995
- Email: gu.zhunyong@zs-hospital.sh.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)
- 2. presence of superior vena cava and/or inferior vena cava reflux disorders
- 3. age greater than 18 years
Exclusion Criteria:
- 1. Inability to establish suitable vascular access
- 2. Pregnant women
- 3. Not agreeing to active life support treatment
- 4. Severe active bleeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: the treatment-as-usual group
we used the single-cannula in femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
|
|
|
Experimental: intervention group
we used the dual-cannula in jugular-femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
|
We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
vasoactive drugs
Time Frame: 144 hours after dual-cannula in jugular-femoral venous
|
doses of vasoactive drugs
|
144 hours after dual-cannula in jugular-femoral venous
|
|
ICU mortality
Time Frame: 28-day ICU mortality
|
Measurement of ICU mortality
|
28-day ICU mortality
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cytokine
Time Frame: 24hous after dual-cannula in jugular-femoral venous
|
Checking cytokine levels by laboratory
|
24hous after dual-cannula in jugular-femoral venous
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Minjie Ju, PHD, Shanghai Zhongshan Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- jv-fv-RRT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.